217 related articles for article (PubMed ID: 22753402)
1. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
Leirisalo-Repo M; Kautiainen H; Laasonen L; Korpela M; Kauppi MJ; Kaipiainen-Seppänen O; Luosujärvi R; Luukkainen R; Karjalainen A; Blåfield H; Uutela T; Ilva K; Julkunen HA; Paimela L; Puolakka K; Moilanen E; Hannonen PJ; Möttönen T;
Ann Rheum Dis; 2013 Jun; 72(6):851-7. PubMed ID: 22753402
[TBL] [Abstract][Full Text] [Related]
2. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.
Rantalaiho V; Kautiainen H; Korpela M; Hannonen P; Kaipiainen-Seppänen O; Möttönen T; Kauppi M; Karjalainen A; Laiho K; Laasonen L; Hakola M; Peltomaa R; Leirisalo-Repo M;
Ann Rheum Dis; 2014 Nov; 73(11):1954-61. PubMed ID: 23908187
[TBL] [Abstract][Full Text] [Related]
3. Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials.
Levitsky A; Wick MC; Möttönen T; Leirisalo-Repo M; Laasonen L; Korpela M; van Vollenhoven RF; Rantalaiho V
Clin Exp Rheumatol; 2016; 34(6):1065-1071. PubMed ID: 27607411
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis.
Rantalaiho V; Puolakka K; Korpela M; Hannonen P; Möttönen T
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S27-31. PubMed ID: 23073350
[TBL] [Abstract][Full Text] [Related]
5. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Hakala M; Järvinen P; Ahonen J; Forsberg S; Leirisalo-Repo M;
Arthritis Rheum; 2005 Jan; 52(1):36-41. PubMed ID: 15641055
[TBL] [Abstract][Full Text] [Related]
6. Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial.
Rantalaiho V; Sandström T; Koski J; Hannonen P; Möttönen T; Kaipiainen-Seppänen O; Yli-Kerttula T; Kauppi MJ; Uutela T; Malmi T; Julkunen H; Laasonen L; Kautiainen H; Leirisalo-Repo M;
Arthritis Care Res (Hoboken); 2019 Nov; 71(11):1450-1458. PubMed ID: 30295425
[TBL] [Abstract][Full Text] [Related]
7. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
Mustila A; Korpela M; Haapala AM; Kautiainen H; Laasonen L; Möttönen T; Leirisalo-Repo M; Ilonen J; Järvenpää S; Luukkainen R; Hannonen P
Clin Exp Rheumatol; 2011; 29(3):500-5. PubMed ID: 21640044
[TBL] [Abstract][Full Text] [Related]
8. Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.
Kuusalo L; Puolakka K; Kautiainen H; Blåfield H; Eklund KK; Ilva K; Kaipiainen-Seppänen O; Karjalainen A; Korpela M; Valleala H; Leirisalo-Repo M; Rantalaiho V;
Scand J Rheumatol; 2015; 44(6):449-55. PubMed ID: 26324784
[TBL] [Abstract][Full Text] [Related]
9. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR
Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
[TBL] [Abstract][Full Text] [Related]
10. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
11. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
[TBL] [Abstract][Full Text] [Related]
12. Remission as the treatment goal--the FIN-RACo trial.
Sokka T; Mäkinen H; Puolakka K; Möttönen T; Hannonen P
Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-74-6. PubMed ID: 17083766
[TBL] [Abstract][Full Text] [Related]
13. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.
van Tuyl LH; Lems WF; Voskuyl AE; Kerstens PJ; Garnero P; Dijkmans BA; Boers M
Ann Rheum Dis; 2008 Nov; 67(11):1574-7. PubMed ID: 18625629
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
[TBL] [Abstract][Full Text] [Related]
15. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
[TBL] [Abstract][Full Text] [Related]
16. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
[TBL] [Abstract][Full Text] [Related]
17. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial.
ter Wee MM; den Uyl D; Boers M; Kerstens P; Nurmohamed M; van Schaardenburg D; Voskuyl AE; Lems WF
Ann Rheum Dis; 2015 Jun; 74(6):1233-40. PubMed ID: 24818633
[TBL] [Abstract][Full Text] [Related]
18. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Möttönen T; Hannonen P; Leirisalo-Repo M; Nissilä M; Kautiainen H; Korpela M; Laasonen L; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Ilva K; Yli-Kerttula U; Puolakka K; Järvinen P; Hakola M; Piirainen H; Ahonen J; Pälvimäki I; Forsberg S; Koota K; Friman C
Lancet; 1999 May; 353(9164):1568-73. PubMed ID: 10334255
[TBL] [Abstract][Full Text] [Related]
19. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Cöster L; Waltbrand E; Zickert A; Theander J; Thörner A; Hellström H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wörnert M; Bratt J
Lancet; 2009 Aug; 374(9688):459-66. PubMed ID: 19665644
[TBL] [Abstract][Full Text] [Related]
20. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
Heimans L; Wevers-de Boer KV; Visser K; Goekoop RJ; van Oosterhout M; Harbers JB; Bijkerk C; Speyer I; de Buck MP; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
Ann Rheum Dis; 2014 Jul; 73(7):1356-61. PubMed ID: 23716067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
